These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31895562)

  • 1. Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-
    Kurasawa O; Miyazaki T; Homma M; Oguro Y; Imada T; Uchiyama N; Iwai K; Yamamoto Y; Ohori M; Hara H; Sugimoto H; Iwata K; Skene R; Hoffman I; Ohashi A; Nomura T; Cho N
    J Med Chem; 2020 Feb; 63(3):1084-1104. PubMed ID: 31895562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase.
    Kurasawa O; Homma M; Oguro Y; Miyazaki T; Mori K; Uchiyama N; Iwai K; Ohashi A; Hara H; Yoshida S; Cho N
    Bioorg Med Chem; 2017 Jul; 25(14):3658-3670. PubMed ID: 28533114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of XL413, a potent and selective CDC7 inhibitor.
    Koltun ES; Tsuhako AL; Brown DS; Aay N; Arcalas A; Chan V; Du H; Engst S; Ferguson K; Franzini M; Galan A; Holst CR; Huang P; Kane B; Kim MH; Li J; Markby D; Mohan M; Noson K; Plonowski A; Richards SJ; Robertson S; Shaw K; Stott G; Stout TJ; Young J; Yu P; Zaharia CA; Zhang W; Zhou P; Nuss JM; Xu W; Kearney PC
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3727-31. PubMed ID: 22560567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor.
    Iwai K; Nambu T; Dairiki R; Ohori M; Yu J; Burke K; Gotou M; Yamamoto Y; Ebara S; Shibata S; Hibino R; Nishizawa S; Miyazaki T; Homma M; Oguro Y; Imada T; Cho N; Uchiyama N; Kogame A; Takeuchi T; Kurasawa O; Yamanaka K; Niu H; Ohashi A
    Sci Adv; 2019 May; 5(5):eaav3660. PubMed ID: 31131319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
    Reichelt A; Bailis JM; Bartberger MD; Yao G; Shu H; Kaller MR; Allen JG; Weidner MF; Keegan KS; Dao JH
    Eur J Med Chem; 2014 Jun; 80():364-82. PubMed ID: 24793884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
    Zhang M; Jiang L; Tao J; Pan Z; He M; Su D; He G; Jiang Q
    Bioorg Med Chem; 2019 Jun; 27(11):2268-2279. PubMed ID: 31014565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Thieno[3,2-
    Cho H; Shin I; Yoon H; Jeon E; Lee J; Kim Y; Ryu S; Song C; Kwon NH; Moon Y; Kim S; Kim ND; Choi HG; Sim T
    J Med Chem; 2021 Aug; 64(16):11934-11957. PubMed ID: 34324343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
    Cheng AN; Lo YK; Lin YS; Tang TK; Hsu CH; Hsu JT; Lee AY
    EBioMedicine; 2018 Oct; 36():241-251. PubMed ID: 30293817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
    Mohamed MFA; Youssif BGM; Shaykoon MSA; Abdelrahman MH; Elsadek BEM; Aboraia AS; Abuo-Rahma GEA
    Bioorg Chem; 2019 Oct; 91():103127. PubMed ID: 31374527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Thieno[2,3-
    Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G
    J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of AS-0141, a Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers.
    Irie T; Asami T; Sawa A; Uno Y; Taniyama C; Funakoshi Y; Masai H; Sawa M
    J Med Chem; 2021 Oct; 64(19):14153-14164. PubMed ID: 34607435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The optimization of aminooxadiazoles as orally active inhibitors of Cdc7.
    Harrington PE; Bourbeau MP; Fotsch C; Frohn M; Pickrell AJ; Reichelt A; Sham K; Siegmund AC; Bailis JM; Bush T; Escobar S; Hickman D; Heller S; Hsieh F; Orf JN; Rong M; San Miguel T; Tan H; Zalameda L; Allen JG
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6396-400. PubMed ID: 24120542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
    Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones.
    Kurasawa O; Oguro Y; Miyazaki T; Homma M; Mori K; Iwai K; Hara H; Skene R; Hoffman I; Ohashi A; Yoshida S; Ishikawa T; Cho N
    Bioorg Med Chem; 2017 Apr; 25(7):2133-2147. PubMed ID: 28284870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
    Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
    Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3,4-Dihydrobenzo[
    Li Y; Zhang L; Yang R; Qiao Z; Wu M; Huang C; Tian C; Luo X; Yang W; Zhang Y; Li L; Yang S
    J Med Chem; 2022 Feb; 65(3):1786-1807. PubMed ID: 34985886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer.
    Li Y; Yang G; Zhang J; Tang P; Yang C; Wang G; Chen J; Liu J; Zhang L; Ouyang L
    J Med Chem; 2021 Aug; 64(16):12022-12048. PubMed ID: 34351741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminopyrimidinone cdc7 kinase inhibitors.
    Woods KW; Lai C; Miyashiro JM; Tong Y; Florjancic AS; Han EK; Soni N; Shi Y; Lasko L; Leverson JD; Johnson EF; Shoemaker AR; Penning TD
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1940-3. PubMed ID: 22326396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.